Publication date: Jul 01, 2024

The COVID-19 pandemic has posed a significant threat to the global healthcare system, presenting a major challenge to antimicrobial stewardship worldwide. This study aimed to provide a comprehensive and up-to-date picture of global antimicrobial resistance (AMR) and antibiotic use in COVID-19 patients. We conducted a systematic review to determine the prevalence of AMR and antibiotic usage among COVID-19 patients receiving treatment in healthcare facilities. Our search encompassed the PubMed, Web of Science, Embase, and Scopus databases, spanning studies published from December 2019 to May 2023. We utilized random-effects meta-analysis to assess the prevalence of multidrug-resistant organisms (MDROs) and antibiotic use in COVID-19 patients, aligning with both the WHO’s priority list of MDROs and the AWaRe list of antibiotic products. Estimates were stratified by region, country, and country income. Meta-regression models were established to identify predictors of MDRO prevalence and antibiotic use in COVID-19 patients. The study protocol was registered with PROSPERO (CRD 42023449396). Among the 11,050 studies screened, 173 were included in the review, encompassing a total of 892,312 COVID-19 patients. MDROs were observed in 42. 9% (95% CI 31. 1-54. 5%, I = 99. 90%) of COVID-19 patients: 41. 0% (95% CI 35. 5-46. 6%) for carbapenem-resistant organisms (CRO), 19. 9% (95% CI 13. 4-27. 2%) for methicillin-resistant Staphylococcus aureus (MRSA), 24. 9% (95% CI 16. 7-34. 1%) for extended-spectrum beta-lactamase-producing organisms (ESBL), and 22. 9% (95% CI 13. 0-34. 5%) for vancomycin-resistant Enterococcus species (VRE), respectively. Overall, 76. 2% (95% CI 69. 5-82. 9%, I = 99. 99%) of COVID-19 patients were treated with antibiotics: 29. 6% (95% CI 26. 0-33. 4%) with “Watch” antibiotics, 22. 4% (95% CI 18. 0-26. 7%) with “Reserve” antibiotics, and 16. 5% (95% CI 13. 3-19. 7%) with “Access” antibiotics. The MDRO prevalence and antibiotic use were significantly higher in low- and middle-income countries than in high-income countries, with the lowest proportion of antibiotic use (60. 1% (95% CI 52. 1-68. 0%)) and MDRO prevalence (29. 1% (95% CI 21. 8-36. 4%)) in North America, the highest MDRO prevalence in the Middle East and North Africa (63. 9% (95% CI 46. 6-81. 2%)), and the highest proportion of antibiotic use in South Asia (92. 7% (95% CI 90. 4-95. 0%)). The meta-regression identified antibiotic use and ICU admission as a significant predictor of higher prevalence of MDROs in COVID-19 patients. This systematic review offers a comprehensive and current assessment of MDRO prevalence and antibiotic use among COVID-19 patients in healthcare facilities. It underscores the formidable challenge facing global efforts to prevent and control AMR amidst the backdrop of the COVID-19 pandemic. These findings serve as a crucial warning to policymakers, highlighting the urgent need to enhance antimicrobial stewardship strategies to mitigate the risks associated with future pandemics.

Semantics

Original Article